{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-335016","form_type":"8-K","ticker":"MNKD","cik":"0000899460","company_name":"MANNKIND CORP","filed_at":"2026-08-05T20:03:26+00:00","discovered_at":"2026-08-05T20:04:00.219130+00:00","generated_at":"2026-08-05T20:04:19.853105+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MannKind Q2 2026 revenue $109.4M (+43% YoY); Afrezza pediatric and Furoscix ReadyFlow approved","bullets":["Q2 total revenue $109.4M, up 43% YoY; Furoscix contributed $22.2M in net sales.","Afrezza net sales $17.0M (-7% YoY); pediatric indication approved May 29, early launch momentum.","Furoscix ReadyFlow autoinjector approved July 23; commercial launch expected late August.","Positive Phase 1b data for nintedanib DPI (MNKD-201) in IPF; global Phase 2 enrolling.","Closed $50M private placement to fund $45M CVR payment from Furoscix ReadyFlow approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-335016","json":"https://secwatch.observer/filing/0001193125-26-335016.json","markdown":"https://secwatch.observer/filing/0001193125-26-335016.md","text":"https://secwatch.observer/filing/0001193125-26-335016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899460/000119312526335016/0001193125-26-335016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899460/000119312526335016/mnkd-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:04:19.853105+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}